B cell alterations during BAFF inhibition with belimumab in SLE

BACKGROUND: Systemic lupus erythematosus (SLE) is a systemic autoimmune disease, which exhibits multiple B cell abnormalities including expanded populations of memory B cells and elevated levels of autoantibodies. Belimumab is a monoclonal antibody targeting the B cell cytokine BAFF (a.k.a. BLyS), a...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramsköld, Daniel, Parodis, Ioannis, Lakshmikanth, Tadepally, Sippl, Natalie, Khademi, Mohsen, Chen, Yang, Zickert, Agneta, Mikeš, Jaromír, Achour, Adnane, Amara, Khaled, Piehl, Fredrik, Brodin, Petter, Gunnarsson, Iva, Malmström, Vivianne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412067/
https://www.ncbi.nlm.nih.gov/pubmed/30593436
http://dx.doi.org/10.1016/j.ebiom.2018.12.035

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412067/
https://www.ncbi.nlm.nih.gov/pubmed/30593436
http://dx.doi.org/10.1016/j.ebiom.2018.12.035

Ejemplares similares